FDA Approves Bristol Myers Squibb’s Cobenfy for Schizophrenia
Landmark FDA approval of Cobenfy represents the first new class of drugs indicated to treat schizophrenia in decades.
October 22, 2026
Landmark FDA approval of Cobenfy represents the first new class of drugs indicated to treat schizophrenia in decades.